HOOKIPA Pharma Management
Management criteria checks 0/4
HOOKIPA Pharma's CEO is Malte Peters, appointed in Jul 2024, has a tenure of 1.25 years. total yearly compensation is $1.67M, comprised of 16.9% salary and 83.1% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth $23.38K. The average tenure of the management team and the board of directors is 1.4 years and 2.8 years respectively.
Key information
Malte Peters
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 16.88% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.4yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 26%
Dec 21
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky
Nov 19HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues
Sep 27The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29%
Aug 13Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge
Jun 22HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth
Apr 28Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts
Mar 24Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023
Aug 11HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%
May 16Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?
Apr 26Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues
Nov 19HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy
Jul 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$73m |
| Dec 31 2024 | US$2m | US$281k | -US$44m |
| Sep 30 2024 | n/a | n/a | -US$43m |
| Jun 30 2024 | n/a | n/a | -US$49m |
| Mar 31 2024 | n/a | n/a | -US$48m |
| Dec 31 2023 | US$232k | n/a | -US$82m |
Compensation vs Market: Malte's total compensation ($USD1.67M) is above average for companies of similar size in the US market ($USD607.94K).
Compensation vs Earnings: Malte's compensation has increased whilst the company is unprofitable.
CEO
Malte Peters (63 yo)
Dr. Malte Peters, MD., is Director at HOOKIPA Pharma Inc. since 2023 and is its Chief Executive Officer since July 22, 2024 and served as its Ad Interim Senior Clinical Advisor from September 2023 until Ma...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.3yrs | US$1.67m | 0.20% $ 23.4k | |
| Executive VP | 1.3yrs | US$1.08m | 0.17% $ 19.8k | |
| Co-Founder & Member of Scientific Advisory Board | 14.8yrs | no data | no data | |
| Chief Research & Development Officer | 1.5yrs | no data | no data |
Experienced Management: HOOK's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.8yrs | US$1.67m | 0.20% $ 23.4k | |
| Executive VP | 2.5yrs | US$1.08m | 0.17% $ 19.8k | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | US$46.34k | no data | |
| Independent Director | 1.3yrs | US$79.53k | 0% $ 0 | |
| Chairman of the Scientific Advisory Board | no data | US$1.42m | no data | |
| Independent Non-Executive Chair | 6.9yrs | US$89.99k | 0.0039% $ 460.7 | |
| Independent Director | 6.5yrs | US$81.32k | 0.0036% $ 425.0 |
Experienced Board: HOOK's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/06 09:04 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HOOKIPA Pharma Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Debjit Chattopadhyay | H.C. Wainwright & Co. |